Bevacizumab: the phoenix of breast oncology?

Lancet Oncol. 2015 Jun;16(6):600-1. doi: 10.1016/S1470-2045(15)70201-9. Epub 2015 May 11.

Authors

Fabrice Andre¹, Elise Deluche², Herve Bonnefoi³

Affiliations

¹ Department of Medical Oncology, Gustave Roussy, Villejuif, France; INSERM Unit U981 and Université Paris Sud, Faculté de Medecine Kremlin Bicetre, Kremlin Bicetre, France. Electronic address: fandre@igr.fr.
² Department of Medical Oncology, Gustave Roussy, Villejuif, France.
³ Department of Medical Oncology, Institut Bergonie, Bordeaux, France.

PMID: 25975636
DOI: 10.1016/S1470-2045(15)70201-9

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols*
Breast Neoplasms / drug therapy*
Female
Humans
Taxoids / administration & dosage*

Substances

Antibodies, Monoclonal, Humanized
Taxoids